Stock HEMISPHERX BIOPHARMA, INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Hemispherx BioPharma, Inc Nyse

Equities

US42366C3016

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
GL
Recent Stockholder Lawsuits In Delaware Challenge Common Advance Notice Bylaw Provisions
AQ
AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
GL
Transcript : AIM ImmunoTech Inc. - Special Call
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series
GL
AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering
GL
AIM ImmunoTech to Participate in Two Upcoming Investor Conferences
GL
Transcript : AIM ImmunoTech Inc., Q1 2024 Earnings Call, May 16, 2024
AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update
GL
AIM ImmunoTech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast
GL
AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®
GL
AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed
MT
AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
GL
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
GL
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
GL
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
GL
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
GL
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
GL
AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AIM Stock
  4. Stock
  5. News Hemispherx BioPharma, Inc